This CME activity is based on the following:

Expert Interview SABCS 2007: Highlights and Clinical Implications for Metastatic Breast Cancer
An interview with Dr. Lee Schwartzberg, available in streaming audio, downloadable podcast, and printable transcription format.

Please read the following CME information for this activity and then select the link below to launch the activity.

Lee Schwartzberg, MD

Dr. Lee Schwartzberg is a senior partner at The West Clinic in Memphis, Tennessee. He did a residency in Internal Medicine at Cornell University and fellowship training in Hematology and Oncology at Memorial Sloan-Kettering Cancer Center where he was chief resident in Medicine. He is a Clinical Professor of Medicine at The University of Tennessee College of Medicine. He serves as the Medical Director of the Baptist Cancer Institute-Stem Cell Transplant Program and the Cancer Assessment Risk Evaluation and Surveillance (CARES) Genetics Program. Dr. Schwartzberg has authored over fifty research papers and serves as the Director of Research for The West Clinic.

 
Learning Objectives

Upon completion of this activity, participants should be able to:

• Consider the clinical impact of emerging therapies on survival and quality of life for metastatic breast cancer.  
• Define the optimal combinations, duration, and schedules of therapy directed against HER2.
• Evaluate new data with regard to the outcomes achieved with novel anti-VEGF and anti-angiogenic treatment strategies in patients with metastatic breast cancer.
• Understand the potential differences and benefits of newer targeted therapies used alone or in combination with regard to their impact on survival, safety, and quality of life.
• Understand novel chemotherapeutic agents emerging in the management of metastatic breast cancer.
  

Supporters

This activity is supported by an educational grant from Bristol-Myers Squibb Company, Wyeth Pharmaceuticals, and an educational donation provided by Amgen.

Faculty and Disclosures

CEC is committed to the provision of CME that is balanced, objective, and evidence based. CEC adheres to Accreditation Council for Continuing Medical Education (ACCME) Essentials and Standards. Accordingly, all parties involved in content development have disclosed any real or apparent conflicts of interest relating to the topics of this educational activity and the disclosure summary follows. CEC has established mechanisms to resolve conflicts of interest should they arise. Participants in CEC CME programs are afforded the opportunity to provide feedback on the quality of individual programs.

Author: Lee Schwartzberg, MD
Disclosure: Dr. Schwartzberg has disclosed that he is on the Speakers’ Bureau for Amgen, Genentech, GSK, and Genomic Health.

Editor: C. Dean Buckner, MD, OncoEd, Inc.
Disclosure: Dr. Buckner has no relevant financial interests to disclose.

Interviewer: Kari Bohlke, ScD, OncoEd, Inc.
Disclosure: Dr. Bohlke has no relevant financial interests to disclose.

Investigational and/or off-label use of commercial products and devices

CEC requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

The presentations in this CME activity might include discussion of investigational and/or unlabeled use of drugs. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Privacy and Confidentiality

OncoEd is committed to respecting your privacy. We've structured our web site so that you can visit OncoEd on the web without identifying yourself or revealing any personal information. If you choose to provide us personally identifiable information, you can be assured that it will only be used to support your relationship with OncoEd.

On some OncoEd web pages, you can make requests, and register to receive materials. The types of personal information collected at these pages are name and contact information. In order to tailor our subsequent communications to you and continuously improve our products and services, we may also ask you to voluntarily provide us with information regarding your experience with cancer, personal or professional interests, demographics and contact preferences.

OncoEd is committed to ensuring the security of your information. To prevent unauthorized access, maintain data accuracy, and ensure the appropriate use of information, we have put in place appropriate physical, electronic, and managerial procedures to safeguard and secure the information we collect online.

OncoEd has links to many other sites and cannot ensure the privacy or security of information you provide to the linked site.

If you have comments or questions about our privacy policy, please send them to this email address: mail@onco-ed.com.

Disclaimer

Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC.

I have read the required CME information.
Yes: Click Here to Launch the Activity
No: Click Here to Return to the Homepage